Great crunching Mita,
So even with a big hit from generics and no incremental revenue from other products, E in yr 2 is still in the region of 5.6cps and at at current P (45c) gives a PE of 8 times. This is a pretty negative scenario and I expect to be the worst case.
Gives a good yardstick to assess tomorrow's developments, but on the face of it were undervalued in the 40's.
Wazz
Ann: Acrux and Eli Lilly to appeal patent ruling on Axiron-ACR.AX, page-26
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
